Hepatocyte growth factor regulates the TGF-β1-induced proliferation, differentiation and secretory function of cardiac fibroblasts

International Journal of Molecular Medicine

Volumn 34, Issue 2, 2014, Pages 381-390

  Yi, Xin ^a   Li, Xiaoyan ^a   Zhou, Yanli ^a   Ren, Shan ^a   Wan, Weiguo ^a   Feng, Gaoke ^a   Jiang, Xuejun ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Akt; c Met; Cardiac fibroblasts; Fibrosis; Hepatocyte growth factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIN D1; CYCLINE; KI 67 ANTIGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN; VON WILLEBRAND FACTOR; ONCOPROTEIN;

ANIMAL CELL; ARTICLE; CARDIAC FIBROBLAST; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SHAPE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; IMMUNOFLUORESCENCE; IN VITRO STUDY; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEART FAILURE; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEART FAILURE; HEPATOCYTE GROWTH FACTOR; HUMANS; MYOFIBROBLASTS; ONCOGENE PROTEIN V-AKT; PROTO-ONCOGENE PROTEINS C-MET; RATS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84904244903     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1782     Document Type: Article

References (63)

1. Venugopal JR, Prabhakaran MP, Mukherjee S, et al: Biomaterial strategies for alleviation of myocardial infarction. J R Soc Interface 9: 1-19, 2012.
2. Writing Group Members; Lloyd-Jones D, Adams RJ, Brown TM, et al: American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121: e46-e215, 2010.
3. Grandi AM, Imperiale D, Santillo R, et al: Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 40: 647-652, 2002. (Pubitemid 35278600)
4. Zhu JN, Chen R, Fu YH, et al: Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat. PLoS One 8: e75557, 2013.
5. Fang L, Beale A, Ellims AH, et al: Associations between fibrocytes and postcontrast myocardial T1 times in hypertrophic cardiomyopathy. J Am Heart Assoc 2: e000270, 2013.
6. Rao AD, Shah RV, Garg R, et al: Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus. Am J Cardiol 112: 73-78, 2013.
7. Engebretsen KV, Lunde IG, Strand ME, et al: Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli. FEBS J 280: 2382-2398, 2013.
8. Ma Y, Halade GV, Zhang J, et al: Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res 112: 675-688, 2013.
9. Bai J, Zhang N, Hua Y, et al: Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts. PLoS One 8: e72120, 2013.
10. Lu D, Soleymani S, Madakshire R and Insel PA: ATP released from cardiac fibroblasts via connexin hemichannels activates profibrotic P2Y2 receptors. FASEB J 26: 2580-2591, 2012.
11. Zhang W, Chancey AL, Tzeng HP, et al: The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation 124: 2106-2116, 2011.
12. Kapoun AM, Liang F, O'Young G, et al: B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94: 453-461, 2004. (Pubitemid 38326280)
13. Vilahur G, Juan-Babot O, Peña E, et al: Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol 50: 522-533, 2011.
14. He W, Zhang L, Ni A, et al: Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci USA 107: 21110-21115, 2010.
15. Baum JR, Long B, Cabo C and Duffy HS: Myofibroblasts cause heterogeneous Cx43 reduction and are unlikely to be coupled to myocytes in the healing canine infarct. Am J Physiol Heart Circ Physiol 302: H790-H800, 2012.
16. Laeremans H, Hackeng TM, van Zandvoort MA, et al: Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation 124: 1626-1635, 2011.
17. Novoyatleva T, Schymura Y, Janssen W, et al: Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. Basic Res Cardiol 108: 325, 2013.
18. Lian H, Ma Y, Feng J, et al: Heparin-binding EGF-like growth factor induces heart interstitial fibrosis via an Akt/mTor/p70s6k pathway. PLoS One 7: e44946, 2012.
19. Zhang Y, Wang Y, Liu Y, et al: Krüppel-like factor 4 transcriptionally regulates TGF-β1 and contributes to cardiac myofibroblast differentiation. PLoS One 8: e63424, 2013.
20. Zhao T, Zhao W, Chen Y, et al: Platelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts. Am J Physiol Heart Circ Physiol 304: H1719-H1726, 2013.
21. Zhu J and Carver W: Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine 58: 368-379, 2012.
22. Gazdhar A, Fachinger P, van Leer C, et al: Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 292: L529-L536, 2007.
23. Li F, Sun JY, Wang JY, et al: Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis. J Control Release 131: 77-82, 2008.
24. Kanemura H, Iimuro Y, Takeuchi M, et al: Hepatocyte growth factor gene transfer with naked plasmid DNA ameliorates dimethylnitrosamine-induced liver fibrosis in rats. Hepatol Res 38: 930-939, 2008.
25. Herrero-Fresneda I, Torras J, Franquesa M, et al: HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int 70: 265-274, 2006. (Pubitemid 44086576)
26. Okayama K, Azuma J, Dosaka N, et al: Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension 59: 958-965, 2012.
27. Yang ZJ, Chen B, Sheng Z, et al: Improvement of heart function in postinfarct heart failure swine models after hepatocyte growth factor gene transfer: comparison of low-, medium- and high-dose groups. Mol Biol Rep 37: 2075-2081, 2010.
28. Nakamura T, Matsumoto K, Mizuno S, et al: Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol Heart Circ Physiol 288: H2131-H2139, 2005. (Pubitemid 40604097)
29. Takeda S, Liu H, Sasagawa S, et al: HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J Clin Invest 123: 3154-3165, 2013.
30. Tsou HK, Chen HT, Hung YH, et al: HGF and c-Met interaction promotes migration in human chondrosarcoma cells. PLoS One 8: e53974, 2013.
31. Ma PC, Tretiakova MS, Nallasura V, et al: Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 97: 368-377, 2007. (Pubitemid 47196754)
32. Lee WJ, Wu LF, Chen WK, et al: Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem Biol Interact 160: 123-133, 2006.
33. Wen X, Li Y, Hu K, et al: Hepatocyte growth factor receptor signaling mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular mesangial cells. Am J Pathol 167: 947-957, 2005. (Pubitemid 41416248)
34. Huang H, Tang QZ, Wang AB, et al: Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension 56: 232-239, 2010.
35. Ai W, Zhang Y, Tang QZ, et al: Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J Cell Biochem 110: 1111-1122, 2010.
36. Yan-Hong F, Hui D, Qing P, et al: Effects of arginine vasopressin on differentiation of cardiac fibroblasts into myofibroblasts. J Cardiovasc Pharmacol 55: 489-495, 2010.
37. Yao J and Eghbali M: Decreased collagen gene expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy. Response of cardiac fibroblasts to thyroid hormone in vitro. Circ Res 71: 831-839, 1992.
38. Liu C, Cao F, Tang QZ, et al: Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. J Nutr Biochem 21: 1238-1250, 2010.
39. Cai J, Yi FF, Bian ZY, et al: Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med 13: 909-925, 2009.
40. Wang X, Khaidakov M, Ding Z, et al: LOX-1 in the maintenance of cytoskeleton and proliferation in senescent cardiac fibroblasts. J Mol Cell Cardiol 60: 184-190, 2013.
41. Wang K, Zhao X, Kuang C, et al: Overexpression of SDF-1α enhanced migration and engraftment of cardiac stem cells and reduced infarcted size via CXCR4/PI3K pathway. PLoS One 7: e43922, 2012.
42. + cells represent highly functional endothelial progenitor cells in murine bone marrow. PLoS One 6: e20219, 2011.
43. Fujita J, Mori M, Kawada H, et al: Administration of granulocyte colony-stimulating factor after myocardial infarction enhances the recruitment of hematopoietic stem cell-derived myofibroblasts and contributes to cardiac repair. Stem Cells 25: 2750-2759, 2007.
44. Adapala RK, Thoppil RJ, Luther DJ, et al: TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. J Mol Cell Cardiol 54: 45-52, 2013.
45. Galie PA, Russell MW, Westfall MV and Stegemann JP: Interstitial fluid flow and cyclic strain differentially regulate cardiac fibroblast activation via AT1R and TGF-β1. Exp Cell Res 318: 75-84, 2012.
46. Fan YH, Dong H, Pan Q, et al: Notch signaling may negatively regulate neonatal rat cardiac fibroblast-myofibroblast transformation. Physiol Res 60: 739-748, 2011.
47. Melchior-Becker A, Dai G, Ding Z, et al: Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype. J Biol Chem 286: 17365-17375, 2011.
48. Kumar S and Gupta S: Thymosin beta 4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in cardiac fibroblasts. PLoS One 6: e26912, 2011.
49. Dai B, Cui M, Zhu M, et al: STAT1/3 and ERK1/2 synergistically regulate cardiac fibrosis induced by high glucose. Cell Physiol Biochem 32: 960-971, 2013.
50. Cao Y, Xu W and Xiong S: Adoptive transfer of regulatory T cells protects against coxsackievirus B3-induced cardiac fibrosis. PLoS One 8: e74955, 2013.
51. Kazakov A, Hall R, Jagoda P, et al: Inhibition of endothelial nitric oxide synthase induces and enhances myocardial fibrosis. Cardiovasc Res 100: 211-221, 2013.
52. Hou X, Zhang Y, Shen YH, et al: PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1. Eur J Pharmacol 715: 196-203, 2013.
53. Sirish P, Li N, Liu JY, et al: Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. Proc Natl Acad Sci USA 110: 5618-5623, 2013.
54. González A, Ravassa S, Beaumont J, López B and Díez J: New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 58: 1833-1843, 2011.
55. Campbell SE, Janicki JS and Weber KT: Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol 27: 1545-1560, 1995
56. Porter KE and Turner NA: Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123: 255-278, 2009.
57. Burstein B, Libby E, Calderone A and Nattel S: Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 117: 1630-1641, 2008. (Pubitemid 351482606)
58. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA and Gerling IC: Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10: 15-26, 2013.
59. Salimath AS, Phelps EA, Boopathy AV, et al: Dual delivery of hepatocyte and vascular endothelial growth factors via a protease-degradable hydrogel improves cardiac function in rats. PLoS One 7: e50980, 2012.
60. Lu F, Zhao X, Wu J, et al: MSCs transfected with hepatocyte growth factor or vascular endothelial growth factor improve cardiac function in the infarcted porcine heart by increasing angiogenesis and reducing fibrosis. Int J Cardiol 167: 2524-2532, 2013.
61. Guo YH, He JG, Wu JL, et al: Hepatocyte growth factor and granulocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. Cytotherapy 10: 857-867, 2008.
62. Lo RS, Wotton D and Massagué J: Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO J 20: 128-136, 2001. (Pubitemid 32099109)
63. Yang J, Dai C and Liu Y: Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol 163: 621-632, 2003. (Pubitemid 36909423)